GeniusAI Detection

 

Deep-learning based cancer detection for breast tomosynthesis

A breakthrough in early breast cancer detection fully integrated into the Dimensions® platform.

empowered by

 
 

Aids in radiologists’ diagnostic performance1

 

Workflow tools to enhance your practice

 

Fully integrated on the Dimensions® platform

Contact a Hologic Representative to learn more.

Clinical Decision Support

Aids in radiologists’ diagnostic performance.1

Lesion Score: Confidence that a suspicious area represents cancer

 
  • PeerView™ marks:

    Outlines the calcifications.

  • Calc marks:

    Indicate calcification clusters.

    Placeholder image
  • Mass marks:

    Indicate soft tisue lesions (mases,densities,and architectural distortions)

    Placeholder image
  • Malc marks:

    Indicate a soft tisue lesion asociatedwitha calcification cluster.

    Placeholder image
  • RightOn™ marks:

    Shows the center of the region of interest.

  • Placeholder image
  • Placeholder image
  • Placeholder image

Calc marks:

Indicate calcification clusters.

Placeholder image
Placeholder image

Mass marks:

Indicate soft tisue lesions (mases,densities,and architectural distortions)

Placeholder image
Placeholder image

Malc marks:

Indicate a soft tisue lesion asociated with a calcification cluster.

Placeholder image
Placeholder image

Workflow Efficiency

Workflow tools enhance your practice.

 

Case Score

Indicates the confidence determined by Al that a case contains a malignant lesion.

Complexity Index

Categorizes cases according to complexity, based on the number of suspicious areas.

Reading Priority Indicator

Flags the most concerning cases at the time of the exam. Results are available in less than a minute to the technologist in the exam room.

Read Time Indicator

Provides an estimate of how much time radiologists would be expected to spend reading a case.

Integration

Fully integrated on the Dimensions® platform.

Our Technical Sales Specialists can assist with planning to ensure a smooth implementation.

 
 
 

References

1. FDA Clearance K201109.
* Based on analyses that do not control type I error and therefore cannot be generalized to specific comparisons outside this particular study. In this study: The average observed AUC was 0.825 (95% CI: 0.783, 0.867) with CAD and 0.794 (95% CI: 0.748, 0.840) without CAD. The difference in observed AUC was +0.031 (95% CI: 0.012, 0.051). The average observed reader sensitivity for cancer cases was 75.9% with CAD and 66.8% without CAD. The difference in observed sensitivity was +9.0% (99% CI: 6.0%, 12.1%). The average observed recall rate for non-cancer cases was 25.8% with CAD and 23.4% without CAD. The observed difference in negative recall rate was +2.4% (99% CI: 0.7%, 4.2%). The average observed case read-time was 52.0s with CAD and 46.3s without CAD. The observed difference in read-time was 5.7s (95% CI: 4.9s to 6.4s).